
Active case
Case Overview
Ozempic®, made by Novo Nordisk, is a popular drug approved to manage blood sugar in patients with type 2 diabetes. It is also commonly prescribed off-label for weight loss. The FDA Ozempic drug label was updated to include warnings about ileus, a potentially fatal gastrointestinal disorder. Other serious potential side effects remain unlisted on the FDA Ozempic warning label.
Key takeaways about Ozempic’s drug label
- Ozempic can cause severe and potentially fatal side effects, including pancreatitis, acute kidney injury and the development of thyroid c-cell tumors (thyroid cancer).
- A new FDA warning on Ozempic cautions users that the medication may cause ileus, a serious gastrointestinal disorder.
- Motley Rice is representing plaintiffs harmed by Ozempic and similar diabetes and weight loss medications. Ozempic lawsuits claim that Novo Nordisk failed to warn patients about dangerous side effects. If you or someone you love suffered an injury, you can speak with our attorneys about your legal options.
FDA warning label for Ozempic
Ozempic® is a glucagon-like peptide 1 (GLP-1) receptor agonist drug made by Novo Nordisk. Its active ingredient is semaglutide. Ozempic is FDA-approved for patients with type 2 diabetes to manage blood sugar and reduce the risk of heart attack and stroke.
Current FDA Ozempic labels include the following side effects under the warnings and precautions section:
- Acute gallbladder disease
- Acute kidney injury
- Hypersensitivity reactions (severe immune responses/allergic reactions)
- Hypoglycemia (extremely low blood sugar)
- Loss of vision caused by diabetic retinopathy
- Pancreatitis
- Risk of thyroid c-cell tumors
Recent updates to Ozempic warning label
FDA Ozempic warnings were most recently updated in September 2023 to include ileus in the drug’s list of adverse reactions. Ileus is included under the section on postmarketing experience. The label states that postmarketing warnings stem from patients’ voluntarily reported reactions to a medication.
Ileus is a severe medical condition caused by a temporary lack of movement in the intestines. It prevents food and waste from moving through the body. Symptoms of ileus can cut off the blood supply to the intestines, causing tissue death. Ileus can also cause pain, infections and intestinal tearing. In some cases, the buildup of unpassed food can create a blockage.
Other adverse reactions listed on Ozempic’s label include:
- Abdominal pain
- Constipation
- Diarrhea
- Dizziness
- Fatigue
- Increased heart rate
- Injection-site reactions
- Nausea
- Vomiting
Understanding FDA drug labels
FDA drug labels can be difficult to understand. Typically, the information directs patients on a medication’s indication, usage and risks. But, it can be difficult to understand the difference between these sections, as warnings and adverse reactions can seem similar.
- Adverse reactions: This section lists the most frequent adverse reactions identified in clinical trials and by postmarketing experience.
- Contraindications: This section identifies clinical situations in which diseases, medical conditions and prior medical histories make the risk of using a drug outweigh its potential benefits. Contraindications on Ozempic’s label warn that using the drug with insulin secretagogue (sulfonylurea) or insulin may increase the risk of hypoglycemia, including severe hypoglycemia.
- Drug interactions: The drug interactions section provides information about potentially harmful drug interactions that could lead to adverse reactions or decrease a drug’s effectiveness.
- FDA warnings and precautions: Warnings and precautions include information about the most severe and clinically significant adverse reactions and safety hazards associated with a drug.
Conditions not on Ozempic’s FDA warning label
Ozempic lawsuit plaintiffs and plaintiffs injured by other GLP-1 RA medications commonly suffer from severe gastrointestinal and digestive issues. Although Ozempic’s label mentions delayed gastric emptying under drug interactions, it doesn’t mention gastroparesis (stomach paralysis) as a risk or warn against it. However, delayed stomach emptying may lead to this permanent and life-threatening condition.
In addition to experiencing gastrointestinal problems and gastroparesis, plaintiffs in diabetes lawsuits and weight loss drug lawsuits have experienced the following off-label side effects from Ozempic and other GLP-1 RA medications:
- Deep vein thrombosis (DVT): Deep vein thrombosis (DVT) is the formation of a blood clot in one of the body’s deep veins, usually in the legs. When blood clots break loose, they can travel through the bloodstream and stick in the lungs, causing a potentially fatal condition called a pulmonary embolism (PE). Studies find that taking semaglutide can increase the risk of developing DVT by 266%. Semaglutide is the active ingredient in Ozempic, Wegovy and Novo Nordisk’s oral diabetes drug, Rybelsus®.
- Esophageal injury: Research links GLP-1 RA medications to a higher risk of acid reflux disease and a severe form of acid reflux called gastroesophageal reflux disease (GERD). GERD can cause more serious esophageal injuries, including inflammation of the esophagus, narrowing of the esophagus and precancerous changes known as Barrett esophagus.
- Intraoperative aspiration: On June 29, 2023, the American Society of Anesthesiologists warned that Ozempic users should stop taking the medication at least one week before elective surgery. Because GLP-1 RAs delay gastric emptying, patients under anesthesia are at an increased risk of regurgitating and aspirating (inhaling) food into the lungs and airways.
- Malnutrition: Ozempic and other diabetes and weight loss medications reduce appetite and slow digestion, which can lead to malnutrition. Users may not get enough calories, protein, calcium, vitamin D and other essential nutrients. Malnutrition can lead to symptoms like bone pain, muscle pain, fatigue and weakness.
- Vision loss: Semaglutide is linked to diabetic retinopathy (which its label warns of) and a condition called nonarteritic anterior ischemic optic neuropathy (NAION). NAION occurs when a lack of blood flow to the optic nerve causes nerve damage. NAION is a leading cause of blindness in adults.
Contact an Ozempic attorney today
If you or someone you love suffered an injury caused by Ozempic or another GLP-1 RA medication, you may qualify for a lawsuit. Complete an online form or contact Attorney Sara Couch with Motley Rice to discuss potential claims and learn more about your legal options.
Initial FDA approval for Ozempic
On December 5, 2017, Novo Nordisk received FDA approval for Ozempic to treat type 2 diabetes in adults. On January 16, 2020, the FDA approved the medication to reduce the risk of cardiovascular events (stroke and heart attack) in adults with type 2 diabetes and known heart disease.
Ozempic is not approved for weight loss, but it has become increasingly popular as off-label weight loss and obesity medication. Its sister medication, Wegovy®, is FDA-approved for this use. Wegovy is also a once-weekly injectable made by Novo Nordisk. It has the same active ingredient (semaglutide) and is essentially the same drug as Ozempic.
The FDA approved Wegovy to treat obesity and encourage weight loss in adults on June 4, 2021. Drug approval was expanded to include treatment of teens aged 12 and older on December 23, 2022. On March 8, 2024, the FDA approved it to reduce the risk of cardiovascular events in overweight and obese patients with established cardiovascular disease.
FAQs about Ozempic’s FDA warning label
What is the new warning on Ozempic?
FDA updated the Ozempic label to warn patients about ileus, a medical condition that can cause severe and life-threatening gastrointestinal problems. The new warning also applies to Ozempic’s sister drug, Wegovy, which is made by the same manufacturer, Novo Nordisk.
Ileus occurs when muscles in the intestines stop moving normally, resulting in the inability to push food and waste out of the body. This lack of movement can cause severe and life-threatening complications, including infection and tissue death.
When did the FDA update the Ozempic label?
The FDA ordered Novo Nordisk to update the Ozempic label to include ileus in September 2023.
The FDA can require safety labeling changes based on new information that becomes available after it approves a drug. The update to Ozempic was driven by postmarketing experiences reported by patients.
As reports about Ozempic complications continue to arise, the FDA may make additional changes to the label.
What is the black box warning on Ozempic?
The FDA has issued a boxed warning (previously called a Black Box Warning) for Ozempic and Wegovy. It alerts users about the association between semaglutide (the active ingredient in Ozempic and Wegovy) and the development of thyroid c-cell tumors, including medullary thyroid carcinoma (MTC). MTC is a rare and deadly form of thyroid cancer.
Boxed warnings are the FDA’s most serious type of warning. Boxed warnings are used when a medication side effect can cause severe harm or death.
Are people filing Ozempic lawsuits?
Yes, Motley Rice is currently representing plaintiffs in Ozempic lawsuits. Cases address dangerous side effects allegedly caused by Ozempic, Wegovy and other GLP-1 drugs. Hundreds of lawsuits have been consolidated into multidistrict litigation (MDL) in the U.S. District Court for the Eastern District of Pennsylvania. As of May 2025, the MDL contained more than 1,800 personal injury claims.
Our medical drug experience
If you or someone you love suffered harm caused by a medication used to treat type 2 diabetes or chronic weight management, you may be eligible for legal action. You could recover compensation for medical bills, lost wages, pain, suffering and more.
Our attorneys have represented thousands of victims hurt by prescription and over-the-counter medications. Our law firm can:
- Review your claim and discuss your options
- Investigate the medication that caused your injury
- Review the drug’s FDA label and the manufacturer’s compliance with FDA regulations
- Inform you about issues that could affect your case
Read more on our medical drug litigation experience.
Do not stop taking a prescribed medication without first consulting with your doctor. Discontinuing a prescribed medication without your doctor's advice can result in injury or death. Ozempic, Wegovy, Rybelsus remain approved by the U.S. Food and Drug Administration.
FDA warning label for Ozempic
Initial FDA approval for Ozempic
FAQs about Ozempic’s FDA warning label
Our medical drug experience
- Sources
- American Medical Association. New FDA warning label for Ozempic and Wegovy—plus how and where to get a free COVID vaccine.
- Cleveland Clinic. GLP-1 Agonists.
- Drugs.com. Ozempic FDA Approval History.
- Drugs.com. Wegovy FDA Approval History.
- FiercePharma. Novo Nordisk's Ozempic gets FDA label update flagging risk of intestinal blockage disorder.
- Gastroenterology Advisor. Short-Acting GLP-1 Receptor Agonists Increase Risk for GERD in Type 2 Diabetes.
- Hathaway JT, Shah MP, Hathaway DB, et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients PrescribedSemaglutide. JAMA Ophthalmol. Published online 2024 July 3.
- Healthline. 5 Common Nutrient Deficiencies You Can Develop on Drugs Like Wegovy and Zepbound.
- Mayo Clinic. Deep vein thrombosis (DVT).
- Mayo Clinic. Gastroparesis.
- Medical News Today. Boxed warnings: What to know.
- Medical News Today. What is ileus?
- National Cancer Institute. Medullary Thyroid Cancer (MTC).
- Ozempic.com. What Is Ozempic® (semaglutide) Injection?
- Penn Medicine. Eye Stroke - Penn Ophthalmology.
- UCLA Health. Semaglutide for weight loss - what you need to know.
- United States District Court Eastern District of Pennsylvania. MDL 3094 In Re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAS) Products Liability Litigation.
- United States Judicial Panel on Multidistrict Litigation. MDL Statistics Report - Distribution of Pending MDL Dockets by Actions Pending.
- U.S. Food & Drug Administration. How Do I Use Prescription Drug Labeling?
- U.S. Food & Drug Administration. Ozempic label.
- U.S. Food & Drug Administration. Rybelsus label.
- U.S. Food & Drug Administration. Safety Labeling Change Orders.
- U.S. Food & Drug Administration. Wegovy label.
- WebMD. Ileus: What Is It?
- Yin DG, Ding LL, Zhou HR, Qiu M, Duan XY. Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials. Endocr J. 2021 Jun 28;68(6):739-742.